Core Viewpoint - He Yuan Bio (688765) has successfully listed on the Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the Sci-Tech Growth tier, with a significant opening increase of 202.82% to a price of 88 CNY per share on its debut [1] Company Overview - He Yuan Bio is an innovative biopharmaceutical company that possesses a globally leading plant bioreactor technology platform [1] - The company has established an independent intellectual property rights system for its rice endosperm cell bioreactor expression system and has developed a comprehensive plant molecular pharming industrialization system [1] - He Yuan Bio has developed multiple products including drugs, pharmaceutical excipients, and research reagents based on its rice endosperm cell bioreactor expression system [1] Product Pipeline - Currently, the company has a total of 8 drug candidates in its research pipeline [1] - The most advanced product, recombinant human serum albumin injection (OsrHSA, HY1001), has received approval from the National Medical Products Administration and has been successfully launched [1] - Additionally, 2 drugs are in Phase II clinical trials, 2 drugs are in Phase I clinical trials, and 1 drug has been approved to commence clinical trials [1] - The company has several other drugs in the research and development stage and has not yet achieved profitability [1]

Group 1: Company Listings - Three companies, Bibete (688759), Heyuan Bio (688765), and Xi'an Yicai (688783), were listed on the Shanghai Stock Exchange, while Taika Ying (920020) was listed on the Beijing Stock Exchange [1] Group 2: Bibete (688759) - Bibete is a biopharmaceutical company focused on innovative drug development for major diseases such as cancer, autoimmune diseases, and metabolic diseases [2] - The actual controller of Bibete is Qian Changgeng, who holds 15.2840% of the shares directly and controls a total of 43.9582% of the shares through agreements with other shareholders [2] - The total amount raised in this issuance is 1.6002 billion yuan, with a net amount of 1.4911 billion yuan allocated for new drug research and development, a research center, and working capital [3] Group 3: Heyuan Bio (688765) - Heyuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [4] - The actual controller is Yang Daichang, who directly holds 15.03% of the shares and controls a total of 29.25% of the voting rights before the issuance [4] - The total amount raised in this issuance is 2.5995 billion yuan, with a net amount of 2.4304 billion yuan used for the construction of an albumin industrialization base, new drug research, and working capital [5] Group 4: Xi'an Yicai (688783) - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers [5] - The controlling shareholder is Beijing Yisiwei Technology Group, which holds 12.73% of the shares directly and controls 25.68% of the shares through agreements with other shareholders [5] - The total amount raised in this issuance is 4.6358 billion yuan, with a net amount of 4.5068 billion yuan allocated for the second phase of the silicon industry base project [6] Group 5: Taika Ying (920020) - Taika Ying is a company driven by technological innovation, focusing on the global tire market for mining and construction [7] - The controlling shareholder is Taika Ying Holdings, which held 72.94% of the shares before the issuance and 58.35% after the issuance [7] - The total amount raised in this issuance is 331.875 million yuan, with a net amount of 290.4395 million yuan used for tire product upgrades and innovation technology development [8]

Group 1 - The article discusses the upcoming IPOs, including two new stock subscriptions and four new listings scheduled for October 28, 2025 [2][3] - The new stocks include He Yuan Bio (688765.SH), Xi'an Yicai (688783.SH), Bi Bei Te (688759.SH), and Tai Kai Ying (920020.BJ) [3][4] - The subscription price for Tai Kai Ying is set at 46.68 yuan with an issuance price-earnings ratio of 34.98 times, compared to the industry average of 44.03 times [4] Group 2 - The company specializes in the research, development, production, and sales of high-speed heavy-load precision gear transmission products, primarily for wind power generation [6] - The company has established a comprehensive business chain from design to production and maintenance services, with capabilities for products ranging from 1.5MW to 22MW [6] - Key financial data shows a projected revenue of 37.15 billion yuan for 2024, down from 44.42 billion yuan in 2023, with a net profit of 5.34 billion yuan [7] Group 3 - The company has a strong technical foundation and has built a mature technology system, enhancing product performance in terms of power density, sealing, stability, and transmission efficiency [8] - The wind power industry is supported by national policies, promoting market development despite previous subsidy cancellations [8][9] - The company faces challenges such as limited financing channels and increasing competition in a market transitioning to price-based competition [10][11] Group 4 - The company has received certifications from authoritative institutions, ensuring high-quality control and a good industry reputation [9] - The company’s future growth may be constrained by its relatively short establishment period and the mismatch between existing capacity and future development plans [11] - The company is also affected by the reliance on foreign suppliers for certain core components, such as bearings, which may impact its competitive edge [11] Group 5 - The second company mentioned focuses on providing professional technical services, including engineering cost, bidding agency, and project management [12] - Financial projections indicate a revenue increase to 3.96 billion yuan in 2024, up from 3.68 billion yuan in 2023 [13][15] - The company benefits from a strong service quality reputation and a comprehensive service offering, but faces challenges such as rising labor costs and fragmented business segments [20][21]

New IPOs and Listings - Two new stocks are available for subscription: Delijia (603092.SH) on the Shanghai Stock Exchange and Zhongcheng Consulting (920003.BJ) on the Beijing Stock Exchange [1] - Four stocks are listed today: Bibete (688759.SH), Xi'an Yicai (688783.SH), Heyuan Bio (688765.SH), and Taikaiying (920020.BJ) [1] Delijia (603092.SH) - Delijia specializes in the R&D, production, and sales of high-speed heavy-load precision gear transmission products, primarily for wind power generation [2][7] - The IPO price is 46.68 CNY per share, with an institutional offering price of 47.68 CNY, and a market capitalization of 16.8 billion CNY [5] - The company has a projected market share of 10.36% globally and 16.22% in China for wind power transmission equipment by 2024, ranking third globally and second in China [7] - Delijia's revenue from onshore wind power is expected to be 36.25 billion CNY in 2024, accounting for 98.57% of its total revenue [7] Zhongcheng Consulting (920003.BJ) - Zhongcheng Consulting focuses on engineering consulting services and has ranked among the top five in Jiangsu Province for engineering cost consulting revenue from 2021 to 2024 [8][11] - The IPO price is 14.27 CNY per share, with a market capitalization of 1.4 billion CNY [11] - The company plans to invest 1.23 billion CNY in building an engineering consulting service network and 0.77 billion CNY in R&D and information technology [11] Taikaiying (920020.BJ) - Taikaiying is the first company in the mining and construction tire segment to be listed on the Beijing Stock Exchange, recognized as the "first tire stock" on the exchange [15][19] - The IPO price is 7.50 CNY per share, with a market capitalization of 750 million CNY [18] - The company holds the number one market share in the domestic market for large-tonnage crane tires [19] Xi'an Yicai (688783.SH) - Xi'an Yicai is a leading manufacturer of 12-inch silicon wafers, ranking first in China and sixth globally in terms of production capacity [21][22] - The IPO price is 8.62 CNY per share, with a market capitalization of 34.81 billion CNY [21] - The company has a projected capacity of 120,000 wafers per month by 2026, which will meet 40% of the demand in mainland China [22] Heyuan Bio (688765.SH) - Heyuan Bio focuses on the research and development of plant-derived recombinant protein expression technology and has developed several pharmaceutical products [33][38] - The IPO price is 29.06 CNY per share, with a market capitalization of 10.39 billion CNY [35] - The company plans to invest 19.09 billion CNY in the construction of a plant for recombinant human serum albumin and 7.94 billion CNY in new drug development [37]

Summary of Key Points Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is set to list its ordinary shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2025, despite not being profitable at the time of listing [1][2]. Group 1: Listing Overview - The company will be included in the Sci-Tech Growth Layer upon listing due to its current unprofitability [2]. - The total share capital after the IPO will be 357.5 million shares, with 89,451,354 shares being newly issued [3]. Group 2: Market Comparisons - The IPO price is set at 29.06 yuan per share, which corresponds to a diluted price-to-book ratio of 3.43 times for 2024, lower than the average for comparable companies in the industry [4]. Group 3: Trading Risks - The stock will have a price fluctuation limit of 20%, but there will be no limit on price changes for the first five trading days, leading to potential volatility [2][4]. - The initial number of freely tradable shares will be 40,978,773, accounting for 11.46% of the total share capital, which may result in liquidity risks due to a limited number of circulating shares [2].

Core Points - The first stock of the Sci-Tech Innovation Growth Tier, He Yuan Bio, has attracted significant market attention during its subscription process [2][3] - Many investors faced issues with subscription due to insufficient permissions, highlighting the varying service quality among brokerage firms [1][5] Company Overview - He Yuan Bio is the first company to successfully pass the review and obtain registration approval under the new fifth set of standards for the Sci-Tech Innovation Board [3] - The total issuance amount for He Yuan Bio is 89.45 million shares, with 14.31 million shares available for online subscription [3] - The maximum subscription limit for investors is 14,000 shares, requiring a minimum market value of 140,000 yuan in the Shanghai market [3] - He Yuan Bio focuses on the research and development of plant molecular medicine technology and products, specifically using a rice endosperm cell expression system [3] - The core product, HY1001, has completed Phase III clinical trials, achieving both primary and secondary endpoints [3] Financial Performance - He Yuan Bio has not yet achieved profitability, with projected revenues of 13.40 million yuan, 24.26 million yuan, 25.22 million yuan, and 12.71 million yuan for the years 2022 to 2025 [3] - The net profit attributable to the parent company is projected to be -144 million yuan, -187 million yuan, -151 million yuan, and -81.63 million yuan for the same period [3] Subscription Process and Challenges - Investors must first open trading permissions for the Sci-Tech Innovation Board and sign a risk disclosure agreement to participate in the Growth Tier [4] - The requirements for opening permissions include maintaining an average asset of at least 500,000 yuan over the past 20 trading days, having at least two years of trading experience, and achieving a risk assessment level of C4 or above [4] - The quality of service from brokerage firms significantly impacts the ease of permission opening, with some firms providing proactive communication and guidance while others do not [5] Market Response and Future Outlook - Investors have called for improved services, suggesting the establishment of a subscription alert mechanism to prevent permission issues from hindering new stock opportunities [6] - Other companies in the Growth Tier, such as Xi'an Yicai and Bibete, are also set to launch subscriptions soon, indicating ongoing interest in this market segment [9]

Group 1 - Four companies, He Yuan Bio (688765.SH), Biobetter (688759.SH), Xi'an Yichai (688783.SH), and Taikai Ying (920020.BJ), were listed today [1] - Two companies, Delijia (603092.SH) and Zhongcheng Consulting (920003.BJ), are open for subscription [1]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is officially launching its IPO process, aiming to raise 2.4 billion yuan primarily for the construction of a recombinant human albumin industrialization base, marking it as one of the first new registered companies in the Sci-Tech Innovation Board [1][2]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and is recognized as an innovative biopharmaceutical company [1][3]. - The company has achieved a significant increase in the expression level of recombinant human albumin in rice from 2.75 grams to 30 grams per kilogram over nearly 19 years of research and development [3]. - Heyuan Biotechnology has built an intelligent production line that meets international standards, capable of producing 12 million bottles of recombinant human albumin injection annually [3]. Group 2: IPO and Fundraising Details - The company plans to raise 2.4 billion yuan, with 1.658 billion yuan allocated for the industrialization base of recombinant human albumin, 642 million yuan for future research and development of in-progress products, and 100 million yuan for working capital [2]. - The IPO application was approved by the Shanghai Stock Exchange on July 1, making it the first company to pass the review and obtain registration approval under the new fifth set of listing standards [1][2]. Group 3: Market Context - The market size for human serum albumin in China reached 36.1 billion yuan in 2023, with projections to grow to 57 billion yuan by 2030, indicating a significant demand for this product [2]. - Over 60% of human serum albumin supply in China relies on imports, highlighting a potential market opportunity for domestic production [2]. - The annual demand for human serum albumin in China is approximately 1,000 tons, all sourced from plasma extraction [2].

Core Viewpoint - He Yuan Bio (688765.SH) has initiated its subscription with an issue price of 29.06 yuan per share, aiming to leverage its innovative plant-based biopharmaceutical technology platform for drug development and commercialization [1] Company Overview - He Yuan Bio is an innovative biopharmaceutical company with a leading global position in plant bioreactor technology, specifically utilizing rice endosperm cell bioreactor expression systems [1] - The company has developed a comprehensive industrialization system for molecular pharming and has multiple products including drugs, pharmaceutical excipients, and research reagents [1] Drug Pipeline - As of the date of the prospectus, the company has eight drugs in its research pipeline, with the most advanced being recombinant human serum albumin injection (OsrHSA, HY1001), which is nearing approval for market launch [1][2] - The core product HY1001 has completed its Phase III clinical trial for liver cirrhosis with hypoalbuminemia, achieving its primary and secondary endpoints with good safety profiles [1][3] Clinical Trials and Regulatory Communication - The company has engaged in discussions with the FDA regarding the design of an international multi-center Phase III clinical trial for HY1001, which, upon successful completion, could lead to approval for all current indications of plasma-derived human serum albumin [2][3] Financial Performance - The company reported revenues of approximately 13.40 million yuan, 24.26 million yuan, and 25.22 million yuan for the years 2022, 2023, and 2024 respectively, while incurring net losses of approximately 144 million yuan, 187 million yuan, and 152 million yuan during the same periods [3][4] - Key financial metrics include total assets of 1.06 billion yuan, equity attributable to shareholders of 601.35 million yuan, and a debt-to-asset ratio of 43.37% as of December 31, 2024 [4]

Group 1 - The number of valid subscription accounts for the online issuance is 3,359,036, with a total valid subscription quantity of 39,602,538,500 shares, resulting in an initial online issuance lottery rate of 0.03613910% [1] - The initial effective subscription multiple for the online issuance was 2,767.09 times, prompting the implementation of a callback mechanism to adjust the scale between offline and online issuances [2] - After the callback mechanism was activated, the final online issuance quantity was 21,509,500 shares, accounting for 29.89% of the total issuance after deducting the final strategic placement [2] Group 2 - The total number of allocation numbers was 79,205,077, with the range of numbers from 100,000,000,000 to 100,079,205,076 [1] - The final online issuance lottery rate after the callback mechanism was 0.05431344% [2] - The offline final issuance quantity was 50,461,346 shares, representing 70.11% of the total issuance after deducting the final strategic placement [2]